{Reference Type}: Journal Article
{Title}: Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.
{Author}: Sakulpisuti C;Charoenphun P;Chamroonrat W;Sakulpisuti C;Charoenphun P;Chamroonrat W;
{Journal}: Molecules
{Volume}: 27
{Issue}: 15
{Year}: Aug 2022 3
{Factor}: 4.927
{DOI}: 10.3390/molecules27154936
{Abstract}: Differentiated thyroid cancer (DTC), arising from thyroid follicular epithelial cells, is the most common type of thyroid cancer. Despite the well-known utilization of radioiodine treatment in DTC, i.e., iodine-131, radioiodine imaging in DTC is typically performed with iodine-123 and iodine-131, with the current hybrid scanner performing single photon emission tomography/computed tomography (SPECT/CT). Positron emission tomography/computed tomography (PET/CT) provides superior visualization and quantification of functions at the molecular level; thus, lesion assessment can be improved compared to that of SPECT/CT. Various types of cancer, including radioiodine-refractory DTC, can be detected by 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), the most well-known and widely used PET radiopharmaceutical. Several other PET radiopharmaceuticals have been developed, although some are limited in availability despite their potential clinical utilizations. This article aims to summarize PET radiopharmaceuticals in DTC, focusing on molecular pathways and applications.